Skip to main content

Advertisement

SpringerLink
Log in

Neuraxial pain relief for intractable cancer pain

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Most patients with cancer pain achieve good analgesia using traditional analgesics and adjuvant medications; however, an important minority of patients (2% to 5%) suffers from severe and refractory cancer pain. For these individuals, spinal analgesics (intrathecal or epidural) provide significant hope for pain relief over months or years of treatment to help improve quality of life. Spinal analgesics have been suggested as the fourth step in the World Health Organization guidelines in the management of cancer pain, and thus the pain physician should be familiar with principles of use. Most patients achieve pain relief using spinal analgesics, with a minimum of complications that are easily managed at home. A variety of opioids, local anesthetics, clonidine, ketamine, and other analgesics are available for the spinal route of administration and should be titrated to clinical effect or intolerable side effect. This article discusses the appropriate selection of patients for spinal analgesics, reviews current recommended infusion systems and current spinal analgesics, discusses possible complications, and includes practical suggestions for patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sloan PA, Slatkin NE, Ahdieh H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 2005, 13:57–65.

    Article  PubMed  Google Scholar 

  2. Melzack R, Ofiesh JG, Mount BM: The Brompton mixture: effects on pain in cancer patients. Can Med Assoc J 1976, 115:125–129.

    PubMed  CAS  Google Scholar 

  3. Schug SA, Zech D, Dorr U: Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990, 5:27–32.

    Article  PubMed  CAS  Google Scholar 

  4. Sloan PA, Melzack R: Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J 1999, 14:35–47.

    Article  PubMed  CAS  Google Scholar 

  5. Sloan PA: The evolving role of interventional pain management in oncology. J Support Oncol 2004, 2:1–11.

    Google Scholar 

  6. Mercandante S, Portenoy RK: Opioid poorly responsive cancer pain, part 3: clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001, 21:338–354.

    Article  Google Scholar 

  7. Meyerson BA: Neurosurgical approaches to pain treatment. Acta Anaesthesiol Scand 2001, 45:1108–1113.

    Article  PubMed  CAS  Google Scholar 

  8. Kedlaya D, Reynolds L, Waldman S: Epidural and intrathecal analgesia for cancer pain. Best Prac Res Clin Anaesth 2002, 16:651–665.

    Article  Google Scholar 

  9. Mercadante S: Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999, 79:1–13.

    Article  PubMed  CAS  Google Scholar 

  10. Melzack R, Wall PD: Pain mechanisms: a new theory. Science 1965, 150:171–179.

    Article  Google Scholar 

  11. Pert CB, Snyder SH: Opiate receptor: demonstration in nervous tissue. Science 1973, 179:1011–1014.

    Article  PubMed  CAS  Google Scholar 

  12. Wang JK, Nauss LA, Thomas JE: Pain relief by intrathecally applied morphine in man. Anesthesiology 1979, 50:149–151.

    Article  PubMed  CAS  Google Scholar 

  13. Mercadante S: Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Symptom Manage 1994, 9:201–207.

    Article  PubMed  CAS  Google Scholar 

  14. Stearns L, Boortz-Marx R, Du Pen S, et al.: Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol 2005, 3:399–408.

    PubMed  CAS  Google Scholar 

  15. Krames ES: Practical issues when using neuraxial infusion. Oncology 1999, 13:S37–S44.

    Google Scholar 

  16. Mercadante S: Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Reg Anesth Pain Med 1999, 24:74–83.

    Article  PubMed  CAS  Google Scholar 

  17. Paice JA, Winkelmuller W, Burchief K, et al.: Clinical realities and economic considerations: efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997, 14:S14–S26.

    Article  PubMed  CAS  Google Scholar 

  18. Follett KA, Hitchon PW, Piper J, et al.: Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain 1992, 49:21–25.

    Article  PubMed  CAS  Google Scholar 

  19. Sallerin-Caute B, Lazorthes Y, Deguine O, et al.: Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance? Neurosurgery 1998, 42:44–49.

    Article  PubMed  CAS  Google Scholar 

  20. Samuelsson H, Malber F, Eriksson M, Hedner T: Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995, 10:105–112.

    Article  PubMed  CAS  Google Scholar 

  21. Nitescu P, Dahm P, Appelgren L, Curelaru I: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of refractory nonmalignant pain. Clin J Pain 1998, 14:17–28.

    Article  PubMed  CAS  Google Scholar 

  22. Du Pen SL, Kharash ED, Williams A, et al.: Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992, 49:293–300.

    Article  PubMed  Google Scholar 

  23. van Dongen RT, Crul BJ, van Egmond J: Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999, 15:166–172.

    Article  PubMed  Google Scholar 

  24. Mercadante S, Villari P, Ferrera P, Arcuri E: Local anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain. Anesth Analg 2003, 97:187–189.

    Article  PubMed  CAS  Google Scholar 

  25. Eisenach JC, Du Pen S, Dubois M, et al.: Epidural clonidine analgesia for intractable cancer pain. Pain 1995, 61:391–399.

    Article  PubMed  CAS  Google Scholar 

  26. Yang CY, Wong CS, Chang JY, Ho ST: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anesth 1996, 43:379–383.

    PubMed  CAS  Google Scholar 

  27. Walker SM, Goudas LC, Cousins MJ, Carr DB: Combination spinal analgesic chemotherapy: a systematic review. Anesth Analg 2002, 95:674–715.

    Article  PubMed  CAS  Google Scholar 

  28. Vranken JH, Troost D, de Hann P, et al.: Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S(+)-ketamine. Anesthesiology 2006, 105:813–818.

    Article  PubMed  CAS  Google Scholar 

  29. Doggrell SA: Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 2004, 13:875–877.

    Article  PubMed  CAS  Google Scholar 

  30. Sloan PA, Hamann SR: Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manage 2006, 2:295–304.

    Google Scholar 

  31. Smith TJ, Coyne PJ: How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol 2003, 1:73–76.

    PubMed  Google Scholar 

  32. Brogan SE: Intrathecal therapy for the management of cancer pain. Curr Pain Headache Rep 2006, 10:254–259.

    Article  PubMed  Google Scholar 

  33. Bedder MD, Burchiel K, Larson A: Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991, 6:368–373.

    Article  PubMed  CAS  Google Scholar 

  34. Han KR, Kim C, Park SK, Kim JS: Distance to the adult cervical epidural space. Reg Anesth Pain Med 2003, 28:95–97.

    Article  PubMed  Google Scholar 

  35. Bennett G, Burchiel K, Buchser E, et al.: Clinical guidelines for intraspinal infusion: report of an expert panel. J Pain Symptom Manage 2000, 20:S37–S43.

    Article  PubMed  CAS  Google Scholar 

  36. Smith TJ, Staats PS, Deer T, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20:4040–4049.

    Article  PubMed  CAS  Google Scholar 

  37. Cerda-Olmedo G, De Andres J, Moliner S: Management of progressive pain in a patient with intramedullary chordoma of the spine. Clin J Pain 2002, 18:128–131.

    Article  PubMed  CAS  Google Scholar 

  38. Lazorthes Y, Sagen J, Sallerin B, et al.: Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain 2002, 87:19–32.

    Article  Google Scholar 

  39. Nitescu P, Sjoberg M, Appelgren L, Curelaru I: Complications of intrathecal opioids and bupivacaine in the treatment of refractory cancer pain. Clin J Pain 1995, 11:45–62.

    Article  PubMed  CAS  Google Scholar 

  40. Basta M, Sloan PA: Epidural hematoma following epidural catheter placement in a patient with chronic renal failure. Can J Anesth 1999, 46:271–274.

    Article  PubMed  CAS  Google Scholar 

  41. Ubogu EE, Lindenberg JR, Werz MA: Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Reg Anesth Pain Med 2003, 28:470–474.

    Article  PubMed  Google Scholar 

  42. van Dongen RT, van Ee R, Crul BJ: Neurological impairment during long-term intrathecal infusion of bupivacaine in cancer patients: a sign of spinal cord compression. Pain 1997, 69:205–209.

    Article  PubMed  Google Scholar 

  43. Allen JW, Horais KA, Tozier NA, et al.: Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs. Anesthesiology 2006, 105:581–589.

    Article  PubMed  CAS  Google Scholar 

  44. Hassenbusch S, Burchiel K, Coffey RJ, et al.: Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002, 3:313–323.

    Article  PubMed  Google Scholar 

  45. Coffey RJ, Burchiel K: Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002, 50:78–86.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Kentucky Medical Center, 800 Rose Street, Suite N218, Lexington, KY, 40536, USA

    Paul A. Sloan MD

Authors
  1. Paul A. Sloan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Sloan MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sloan, P.A. Neuraxial pain relief for intractable cancer pain. Current Science Inc 11, 283–289 (2007). https://doi.org/10.1007/s11916-007-0205-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-007-0205-5

Keywords

Search

Navigation